# Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma

> **NCT04570410** · PHASE2 · COMPLETED · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 30 (actual)

## Conditions studied

- Bladder Urothelial Carcinoma

## Interventions

- **PROCEDURE:** primary focal resection plus lymph node dissection
- **DRUG:** Tislelizumab
- **DRUG:** Gemcitabine plus cisplatin

## Key facts

- **NCT ID:** NCT04570410
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-01
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-04-15
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2025-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04570410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04570410, "Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04570410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*